Skip to main content

Targeting HER2-Mutated NSCLC With Zongertinib

Rapid Reactions
WCLC 2024 HER2-Mutated NSCLC
Videos

Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.

Portrait of Beth Sandy, MSN, CRNP, FAPO

Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Sponsored by

Boehringer Ingelheim Logo

Get TOP in Your Inbox

Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!

SUBSCRIBE

Related Items

Longer-Term Follow-Up of Amivantamab + Lazertinib vs Osimertinib From the MARIPOSA Study
Videos
Rapid Reactions
Zongertinib, a Novel HER2-Specific Tyrosine Kinase Inhibitor for HER2-Positive Solid Tumors with Brain Metastases
Videos
Rapid Reactions
HARMONi-2: Phase 3 Study of Ivonescimab vs Pembrolizumab in 1L Treatment for Patients with PD-L1-Positive Advanced NSCLC
Videos
Rapid Reactions
Updated Data From ASCO of Beamion LUNG-1, a Phase 1a/1b Trial of Zongertinib in Patients With HER2 Aberration-Positive Solid Tumors
Videos
Rapid Reactions